The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Open accessAbstract
BACKGROUND: There is evidence that medications or vitamins that increase the levels of brain catecholamines and protect against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidase inhibitor selegiline (10 mg a day), alpha-tocopherol (vitamin E, 2000 IU a day), both selegiline and alpha-tocopherol, or placebo for two years. The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3). RESULTS: Despite random assignment, the baseline score on the Mini-Mental State Examination was higher in the placebo group than in the other three groups, and this variable was highly predictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini-Mental State Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegiline (median time, 655 days; P=0.012), alpha-tocopherol (670 days, P=0.001) or combination therapy (585 days, P=0.049), as compared with the placebo group (440 days). CONCLUSIONS: In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“To date, none of the tested compounds have proven effective (Sano et al., 1997; Petersen et al., 2005; Pham and Plakogiannis, 2005; DeKosky et al., 2008).”
From The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease (2011) · cites this paper as Sano et al., 1997
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following a report of success of high-dose vitamin E in keeping late-stage AD patients out of long-term care facilities longer than patients on a placebo81, other studies with vitamin E have been less impressive70,78,80.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
In the citing paper
“high-dose vitamin E (1000 IU twice daily was the regimen tested) may be considered based on results of 2 RCTs that supported approximately 20% lower rate of ADL decline over approximately 2 to 3 years; there were no concerning safely signals or increased mortality with high-dose vitamin E. 127,128”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117
Pryor, W. A. (1976) · Cited by 1,876
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group (1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,222
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,000
The Free Radical Theory of Aging
Harman, D. (2003) · Antioxidants and Redox Signaling · doi:10.1089/152308603770310202 · Cited by 935
Research works printed but not linked: 1
- Holm S, 1979, Scand J Stat, 6, 65
Cited by
Sorted by citations
Items 801–900 of 1,005
Economics of dementia and pharmacoeconomics of dementia therapy
Fillit, H. M., & Hill, J. W. (2005) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2005.03.005 · Cited by 58
Shimazu, S., & Miklya, I. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.11.016 · Cited by 57
Koppaka, V., Paul, C., Murray, I. V. J., & Axelsen, P. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301334200 · Cited by 57
Dinehart, S. M., & Henry, L. (2005) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2005.31726 · Cited by 57
Nutritional status determinants and cognition in the elderly
Donini, L. M., Felice, M. R. D., & CANNELLA, C. (2007) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2007.01.022 · Cited by 57
Memories Are Made of This: Recent Advances in Understanding Cognitive Impairments and Dementia
Banks, W. A., & Morley, J. E. (2003) · The Journals of Gerontology Series A · doi:10.1093/gerona/58.4.m314 · Cited by 57
Antioxidant strategies in protection against neurodegenerative disorders
Tan, D.-X., Manchester, L. C., Sainz, R. M., Mayo, J. C., Alvares, F. L., & Reiter, R. J. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.10.1513 · Cited by 57
Barton, D. L., & Loprinzi, C. L. (2002) · Clinical Breast Cancer · doi:10.3816/cbc.2002.s.023 · Cited by 57
Peptidyl epoxides as selective protease inactivators
Albeck, A. (2000) · Drug Development Research · doi:10.1002/1098-2299(200007/08)50:3/4 · Cited by 12
Oxidative Stress Treatment for Clinical Trials in Neurodegenerative Diseases
Ienco, E. C., LoGerfo, A., Carlesi, C., Orsucci, D., Ricci, G., Mancuso, M., & Siciliano, G. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110164 · Cited by 56
Effect of Vitamin E on Learning and Memory Deficit in Aged Rats
Takatsu, H., OWADA, K., Abe, K., NAKANO, M., & Urano, S. (2009) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.55.389 · Cited by 56
Leukocyte transmigration across the blood-brain barrier: perspectives on neuroAIDS
Roberts, T. K. (2009) · Frontiers in bioscience · doi:10.2741/3631 · Cited by 56
Lipid peroxidation is essential for phospholipase C activity and IP3 related calcium signal
Domijan, A., Kovac, S., & Abramov, A. Y. (2013) · Journal of Cell Science · doi:10.1242/jcs.138370 · Cited by 56
Montine, T. J., Sonnen, J. A., Montine, K. S., Crane, P. K., & Larson, E. B. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322555 · Cited by 56
Pharmacotherapy of Alzheimer Disease
Seow, D. C. C., & Gauthier, S. G. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705201003 · Cited by 56
Bassett, C. N., Neely, M. D., Sidell, K. R., Markesbery, W. R., Switt, L. L., & Montine, T. J. (1999) · Lipids · doi:10.1007/s11745-999-0478-1 · Cited by 56
A review of select vitamins and minerals used by postmenopausal women
Dennehy, C. E., & Tsourounis, C. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.06.003 · Cited by 56
Tratamento farmacológico da doença de Alzheimer
Forlenza, O. V. (2005) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832005000300006 · Cited by 56
Veld, B. A. I. (2002) · Epidemiologic Reviews · doi:10.1093/epirev/mxf001 · Cited by 56
Identifying Dementia in the Primary Care Practice
Solomon, P. R., Calvo, V., Adams, F., DeVeaux, R. D., Pendlebury, W. W., & Sullivan, D. M. (2000) · International Psychogeriatrics · doi:10.1017/s1041610200006608 · Cited by 56
Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
Caltagirone, C., Bianchetti, A., Luca, M. D., Mecocci, P., Padovani, A., Pirfo, E., Scapicchio, P., Senin, U., Trabucchi, M., & Musicco, M. (2005) · Drugs & Aging · doi:10.2165/00002512-200522001-00002 · Cited by 55
Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer’s Disease
Kumar, R., Kumar, V., Kumar, B., Thakur, A., & Dwivedi, A. R. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210512005508 · Cited by 55
Andrade, S., Nunes, D., Dabur, M., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010212 · Cited by 55
Therapeutic effect of targeted antioxidant natural products
Mukherjee, S., Chopra, H., Goyal, R., Jin, S., Dong, Z., Das, T., & Bhattacharya, T. (2024) · Discover Nano · doi:10.1186/s11671-024-04100-x · Cited by 57
Micronutrient supplementation in mild Alzheimer disease patients
Planas, M. (2003) · Clinical Nutrition · doi:10.1016/s0261-5614(03)00106-7 · Cited by 55
Alzheimer's disease: Only prevention makes sense
Viña, J., & Sanz‐Ros, J. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13005 · Cited by 55
George, E., & Reddy, P. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190232 · Cited by 55
Vitamin E Regulation of Mitochondrial Superoxide Generation
Chow, C. K. (2001) · Neurosignals · doi:10.1159/000046879 · Cited by 55
Statin use and the risk of Alzheimer's disease: The MIRAGE Study
Green, R. C., McNagny, S. E., Jayakumar, P., Cupples, L. A., Benke, K. S., Farrer, L. A., & MIRAGE Study Group (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.02.003 · Cited by 55
Antioxidants for the treatment of mild cognitive impairment
Mecocci, P., Mariani, E., Cornacchiola, V., & Polidori, M. C. (2004) · Neurological Research · doi:10.1179/016164104225017659 · Cited by 55
Positron Emission Tomography Scans Obtained for the Evaluation of Cognitive Dysfunction
Silverman, D. H. S., Mosconi, L., Ercoli, L. M., Chen, W., & Small, G. W. (2008) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2008.02.006 · Cited by 55
Rüther, E., Ritter, R., Apecechea, M., Freytag, S., Gmeinbauer, R., & Windisch, M. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070061 · Cited by 55
Onodera, K., Nao-omi, O. M. O. I., Fukui, K., Hayasaka, T., Shinkai, T., Suzuki, S., Abe, K., & Urano, S. (2003) · Free Radical Research · doi:10.1080/1071576031000090019 · Cited by 55
Molecular pathogenesis of sporadic and familial forms of Alzheimer's disease
Ray, W. J., Ashall, F., & Goate, A. (1998) · Molecular Medicine Today · doi:10.1016/s1357-4310(98)01229-5 · Cited by 55
Yang, N., Zhang, Q., Chen, J., Wu, S., Chen, R., Yao, L., Li, B., Liu, X., Zhang, R., & Zhang, Z. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1144326 · Cited by 54
Implications of early treatment among Medicaid patients with Alzheimer's disease
Geldmacher, D., Kirson, N. Y., Birnbaum, H. G., Eapen, S., Kantor, E., Cummings, A. K. G., & Joish, V. N. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.015 · Cited by 54
IS THERE A RELATIONSHIP BETWEEN HIGH C-REACTIVE PROTEIN (CRP) LEVELS AND DEMENTIA?
Mancinella, A., Mancinella, M., Carpinteri, G., Bellomo, A., FOSSATI, C., Gianturco, V., Iori, A., Ettorre, E., Troisi, G., & Marigliano, V. (2009) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2009.09.028 · Cited by 54
Sonnen, J. A., Larson, E. B., Gray, S. L., Wilson, A. M., Kohama, S. G., Crane, P. K., Breitner, J. C. S., & Montine, T. J. (2009) · Annals of Neurology · doi:10.1002/ana.21508 · Cited by 54
Alzheimer Disease and Its Management
Samanta, M. K., Wilson, B., Santhi, K., Kumar, K. P. S., & Suresh, B. (2006) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000208274.80496.f1 · Cited by 54
ONOFRJ, M. C., Thomas, A., Luciano, A. L., Iacono, D., Rollo, A. D., D’Andreamatteo, G., & Iorio, A. D. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200207000-00004 · Cited by 54
Jia, X., McNeill, G., & Avenell, A. (2008) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2008.00887.x · Cited by 54
Memory Assessment in Studies of Cognition-Enhancing Drugs for Alzheimer??s Disease
Simard, M., & van Reekum, R. (1999) · Drugs & Aging · doi:10.2165/00002512-199914030-00004 · Cited by 54
Soft-diet feeding decreases dopamine release and impairs aversion learning in Alzheimer model rats
Kushida, S., Kimoto, K., Hori, N., Toyoda, M., Karasawa, N., Yamamoto, T., Kojo, A., & Onozuka, M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.05.017 · Cited by 54
Free radical biology in neurological manifestations: mechanisms to therapeutics interventions
Tripathi, R. S., Gupta, R. V., Sahu, M., Srivastava, D., Das, A., Ambasta, R. K., & Kumar, P. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16693-2 · Cited by 54
Are Certain Lifestyle Habits Associated with Lower Alzheimer's Disease Risk?
Arab, L. R., & Sabbagh, M. N. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091573 · Cited by 53
He, X.-L., Zhou, W.-Q., Ming-gang, B., & Du, G. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.084 · Cited by 53
Evaluation of oxidative stress after fractures. A preliminary study.
Prasad, G., Dhillon, M. S., Khullar, M., & Nagi, O. N. (2003) · PubMed · Cited by 53
Gay, N. H., Suwanjang, W., Ruankham, W., Songtawee, N., Wongchitrat, P., Prachayasittikul, V., Prachayasittikul, S., & Phopin, K. (2020) · RSC Advances · doi:10.1039/c9ra06056a · Cited by 53
Stefanello, F. M., Chiarani, F., Kurek, A. G., Wannmacher, C. M. D., Wajner, M., & Wyse, Â. T. D. S. (2005) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.06.003 · Cited by 53
Whitehouse, P. J., & Moody, H. R. (2006) · Dementia · doi:10.1177/1471301206059752 · Cited by 53
Challenges to demonstrating disease‐modifying effects in Alzheimer's disease clinical trials
Cummings, J. L. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.07.001 · Cited by 53
Martín, A., Prior, R. L., Shukitt‐Hale, B., Cao, G., & JOSEPH, J. (2000) · The Journals of Gerontology Series A · doi:10.1093/gerona/55.3.b144 · Cited by 53
Vitamin E binding protein A famin Protects Neuronal Cells in vitro
Heiser, M., Hutter‐Paier, B., Jerković, L., Pfragner, R., Windisch, M., Becker-André, M., & Dieplinger, H. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_32 · Cited by 53
Knoll, J. E., Yoneda, F., Knoll, B., Ohde, H., & Miklya, I. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702995 · Cited by 53
Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Evans, J. R., & Henshaw, K. S. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000253.pub2 · Cited by 53
Zhou, X., Li, Y., Shi, X., & Ma, C. (2016) · PubMed · Cited by 56
The promising role of natural products in Alzheimer's disease
da Rosa, M. M., de Amorim, L. C., Alves, J. V. D. O., Aguiar, I. F. D. S., Oliveira, F. G. D. S., da Silva, M. V., & dos Santos, M. T. C. (2022) · Brain Disorders · doi:10.1016/j.dscb.2022.100049 · Cited by 53
Nutritional supplementation in Down syndrome: theoretical considerations and current status
Ani, C. C., Grantham‐McGregor, S., & Muller, D. P. R. (2000) · Developmental Medicine & Child Neurology · doi:10.1017/s0012162200000359 · Cited by 52
Nootropics, Functional Foods, and Dietary Patterns for Prevention of Cognitive Decline
Bonetti, F., Brombo, G., & Zuliani, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805376-8.00019-8 · Cited by 52
Yang, T., & Zhang, F. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314804 · Cited by 52
Farias, G. A., Guzmán‐Martínez, L., Delgado, C., & Maccioni, R. B. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132741 · Cited by 52
Muñoz, F. J., Opazo, C., Gil‐Gómez, G., Tapia, G., Fernández, V., Valverde, M. A., & Inestrosa, N. C. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03081.2002 · Cited by 52
HIV-associated dementia, mitochondrial dysfunction, and oxidative stress
Valcour, V., & Shiramizu, B. (2004) · Mitochondrion · doi:10.1016/j.mito.2004.05.009 · Cited by 52
Microbiological production of tocopherols: current state and prospects
Ogbonna, J. C. (2009) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-009-2104-7 · Cited by 53
Diagnosis, Management, and Treatment of Alzheimer Disease
Richards, S. S., & Hendrie, H. C. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.8.789 · Cited by 52
Milatović, D., VanRollins, M., Li, K., Montine, K. S., & Montine, T. J. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.03.037 · Cited by 52
Ibrahim, N. F., Yanagisawa, D., Durani, L. W., Hamezah, H. S., Damanhuri, H. A., Ngah, W. Z. W., Tsuji, M., Kiuchi, Y., Ono, K., & Tooyama, I. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160685 · Cited by 52
Wu, L., Xian, X., Tan, Z., Dong, F., Xu, G., Zhang, M., & Zhang, F. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03245-7 · Cited by 51
Savica, R., & Petersen, R. C. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.11.006 · Cited by 51
Translational Research on the Way to Effective Therapy for Alzheimer Disease
Rosenberg, R. N. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1186 · Cited by 51
Natural antioxidants and neurodegenerative diseases
Bastianetto, S. (2004) · Frontiers in bioscience · doi:10.2741/1493 · Cited by 51
Maezawa, I., Jin, L., Woltjer, R. L., Maeda, N., Martin, G. M., Montine, T. J., & Montine, K. S. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02818.x · Cited by 51
Pathology and Pathways of Alzheimer's Disease with an Update on New Developments in Treatment
DeKosky, S. T. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.5157.x · Cited by 51
Alzheimer's disease: molecular concepts and therapeutic targets
Fassbender, K. C., Masters, C. L., & Beyreuther, K. T. (2001) · Die Naturwissenschaften · doi:10.1007/s001140100237 · Cited by 51
Juurlink, B. H. J. (2001) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y00-120 · Cited by 51
Whitmore, C. A., Haynes, J. R., Behof, W. J., Rosenberg, A. J., Tantawy, M. N., Hachey, B. C., Wadzinski, B. E., Spiller, B. W., Peterson, T. E., Paffenroth, K. C., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15060742 · Cited by 50
Structure-Based Design of Novel MAO-B Inhibitors: A Review
Mateev, E., Georgieva, M., Mateeva, A., Zlatkov, A., Ahmad, S., Raza, K., Azevedo, V., & Barh, D. (2023) · Molecules · doi:10.3390/molecules28124814 · Cited by 50
Chaparro, J. M., Holm, D. G., Broeckling, C. D., Prenni, J. E., & Heuberger, A. L. (2018) · Frontiers in Nutrition · doi:10.3389/fnut.2018.00036 · Cited by 50
Scales as outcome measures for Alzheimer's disease
Black, R. S., Greenberg, B., Ryan, J. M., Posner, H. B., Seeburger, J. L., Amatniek, J. C., Resnick, M., Mohs, R. C., Miller, D. S., Saumier, D., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.667 · Cited by 50
Yamagata, K., Ichinose, S., & Tagami, M. (2004) · Hypertension Research · doi:10.1291/hypres.27.271 · Cited by 50
LOCKWOOD, P. A., Ewy, W., Hermann, D. J., & Holford, N. H. G. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9048-8 · Cited by 50
Chronological primacy of oxidative stress in Alzheimer disease
Smith, M. A., Nunomura, A., Lee, H., Zhu, X., Moreira, P. I., Ávila, J., & Perry, G. L. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.09.021 · Cited by 50
Diet and Neurocognition: Review of Evidence and Methodological Considerations
Smith, P. J., & Blumenthal, J. A. (2010) · Current Aging Science · doi:10.2174/1874609811003010057 · Cited by 50
Modulation of Radiation‐Induced Disturbances of Antioxidant Defense Systems by Ginsan
Han, Y., Son, S.-J., Akhalaya, M. Y., Платонов, А. Г., Son, H., Lee, K.-H., Yun, Y., & Song, J. (2005) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/neh123 · Cited by 50
Ancelin, M., Christen, Y., & Ritchie, K. A. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000102567 · Cited by 50
Treatment of Alzheimer's Disease — Searching for a Breakthrough, Settling for Less
Drachman, D. A., & Leber, P. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361710 · Cited by 50
Recent Advances in Targeting Transition Metals (Copper, Iron, and Zinc) in Alzheimer’s Disease
Singh, R., Panghal, A., Jadhav, K., Thakur, A., Verma, R. K., Singh, C., Goyal, M., Kumar, J., & Namdeo, A. G. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04256-8 · Cited by 50
Panza, F., Solfrizzi, V., Frisardi, V., Imbimbo, B. P., Capurso, C. A., D’Introno, A., Colacicco, A. M., Seripa, D., Vendemiale, G., Capurso, A., et al. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03327445 · Cited by 49
Navé, S., Doody, R. S., Boada, M., Grimmer, T., Savola, J., Delmar, P., Pauly-Evers, M., Nikolcheva, T., Czech, C., Borroni, E., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161309 · Cited by 49
Mechanisms of Mitochondrial Malfunction in Alzheimer’s Disease: New Therapeutic Hope
Nabi, S. U., Khan, A., Siddiqui, E. M., Rehman, M. U., Alshahrani, S., Arafah, A. M., Mehan, S., Alsaffar, R. M., Alexiou, A. T., & Shen, B. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4759963 · Cited by 51
Non-pharmacologic prevention of Alzheimer’s disease: nutritional and life-style risk factors
Weih, M., Wiltfang, J., & Kornhuber, J. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0704-x · Cited by 49
Effects of vitamin E against aluminum neurotoxicity in rats
Nedzvetsky, V. S., Tuzcu, M., Yaşar, A., Tikhomirov, A. A., & Baydaş, G. (2006) · Biochemistry (Moscow) · doi:10.1134/s0006297906030023 · Cited by 49
Wyse, Â. T. D. S., Stefanello, F. M., Chiarani, F., Delwing, D., Wannmacher, C. M. D., & Wajner, M. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000013741.81436.e8 · Cited by 49
Reduction of inclusion body pathology in ApoE-deficient mice fed a combination of antioxidants
Veurink, G. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00042-x · Cited by 49
Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia
Bjugstad, K. B., Flitter, W. D., Garland, W., Su, G. C., & Arendash, G. W. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00351-5 · Cited by 49
Alzheimer Disease Therapeutics
Irizarry, M. C., & Hyman, B. T. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.10.923 · Cited by 49
Acetylcholinesterase inhibitors for Alzheimer's disease
Flicker, L. A. (1999) · BMJ · doi:10.1136/bmj.318.7184.615 · Cited by 49
Hydrogen peroxide induces neurite degeneration: Prevention by tocotrienols
Fukui, K., Takatsu, H., Koike, T., & Urano, S. (2011) · Free Radical Research · doi:10.3109/10715762.2011.567984 · Cited by 48
Cho, S. O., Ban, J. Y., Kim, J. Y., Jeong, H. Y., Lee, I. S., Song, K., Bae, K., & Seong, Y. H. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08271fp · Cited by 48
Danta, C. C., & Piplani, P. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.942218 · Cited by 48
Metadata
- Authors
- Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., Schneider, L. S., & Thal, L. J.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- University of California, Irvine (US)
- University of South Florida (US)
- University of Southern California (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-04-24
- Volume
- 336
- Issue
- 17
- Pages
- 1216-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2326200998
- Cited by
- 2,380
- References
- 36
- Citations by year
- 2026: 19 · 2025: 23 · 2024: 39 · 2023: 39 · 2022: 41 · 2021: 38 · 2020: 44 · 2019: 43 · 2018: 44 · 2017: 47 · 2016: 55 · 2015: 54 · 2014: 72 · 2013: 62 · 2012: 82
- FWCI
- 118.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U01‐AG10483, U01AG010483, U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, selegiline, alpha-tocopherol, vitamin E, monoamine oxidase inhibitors, combination therapy, disease progression, dementia, activities of daily living, Mini-Mental State Examination, oxidative stress, catecholamines
- MeSH terms
- Activities of Daily Living, Aged, Alzheimer Disease, Cognition, Double-Blind Method, Drug Combinations, Female, Humans, Institutionalization, Male, Mental Status Schedule, Monoamine Oxidase Inhibitors, Selegiline, Vitamin E, Proportional Hazards Models, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
